Recent News for ODT - Odonate Therapeutics, Inc.

Date Title
Aug 6 Biopharma Investing With Avisol Capital: A Careful Balance Of Rules, Instincts (Podcast)
Jul 24 Odonate Therapeutics EPS beats by $0.05
Jul 24 Odonate Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2019
Jul 9 Here's Why Odonate Therapeutics Stock Jumped 70.7% in June
Jul 2 The Daily Biotech Pulse: Celyad To Advance Leukemia Drug To Clinical Trial, Positive Data For Teva's Migraine Drug
Jun 28 Odonate Therapeutics Inc (ODT) CEO Kevin C Tang Bought $20 million of Shares
Jun 28 The Daily Biotech Pulse: Chiasma To Join R3K Index, EU Rejects Amgen's Osteoporosis Drug Application, Karuna IPO
Jun 27 The Daily Biotech Pulse: Verrica Rallies, Aclaris Flunked Hair Loss Study, 3 Biotechs To IPO
Jun 26 Odonate Therapeutics: Making Taxanes Orally Available
Jun 26 Odonate Therapeutics prices follow-on offering at $26/share
Jun 26 Odonate Therapeutics Announces Pricing of Public Offering of Shares of Common Stock
Jun 25 Odonate readies $100M equity offering
Jun 25 Odonate Therapeutics Announces Public Offering of Shares of Common Stock
Jun 24 34 Stocks Moving In Monday's Pre-Market Session
Jun 19 Odonate Therapeutics Inc (ODT) CEO Kevin C Tang Bought $1.3 million of Shares
Jun 11 Odonate Therapeutics Inc (ODT) CEO Kevin C Tang Bought $2.1 million of Shares
Jun 3 Independent Data Monitoring Committee (IDMC) Recommends CONTESSA Continue with No Modifications following Planned Interim Efficacy Futility Analysis
May 29 Odonate Therapeutics to Present at the Jefferies 2019 Global Healthcare Conference
May 8 Jazz Pharma (JAZZ) Q1 Earnings and Sales Beat Estimates
May 6 Odonate Therapeutics (ODT) Investor Presentation - Slideshow
May 6 Small Drug Stocks Outlook: Near-Term Prospects Encouraging
Apr 25 Odonate Therapeutics reports Q1 results
Apr 25 Odonate Therapeutics Announces Financial Results for the Three Months Ended March 31, 2019
Apr 2 PLAY, GME and ADXS among after hours movers
Apr 2 Tesetaxel Brain Concentrations Exceeded Concentrations Required for Tumor Killing for Sustained Period of Time in Preclinical Testing
Back to the Main ODT Page...